MA46463B1 - Composés de pyrazolo[1,5-a]pyridine substitués en tant qu'inhibiteurs de la kinase ret - Google Patents

Composés de pyrazolo[1,5-a]pyridine substitués en tant qu'inhibiteurs de la kinase ret

Info

Publication number
MA46463B1
MA46463B1 MA46463A MA46463A MA46463B1 MA 46463 B1 MA46463 B1 MA 46463B1 MA 46463 A MA46463 A MA 46463A MA 46463 A MA46463 A MA 46463A MA 46463 B1 MA46463 B1 MA 46463B1
Authority
MA
Morocco
Prior art keywords
ret kinase
kinase inhibitors
pyridine compounds
substituted pyrazolo
ret
Prior art date
Application number
MA46463A
Other languages
English (en)
Other versions
MA46463A (fr
Inventor
Li Ren
Steven W Andrews
Tony P Tang
Yutong Jiang
Julia Haas
Sean Aronow
Barbara J Brandhuber
Adam Cook
Gabrielle R Kolakowski
Elizabeth A Mcfaddin
Megan L Mckenney
Andrew T Metcalf
David A Moreno
James F Blake
James Collier
Oren T Mcknulty
Ginelle A Ramann
Shane M Walls
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Priority claimed from PCT/US2017/055993 external-priority patent/WO2018071454A1/fr
Publication of MA46463A publication Critical patent/MA46463A/fr
Publication of MA46463B1 publication Critical patent/MA46463B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

L'invention concerne des composés de formule i : (i) ou un sel ou un solvate pharmaceutiquement acceptable de ceux-ci, dans laquelle a, b, x 1 , x 2 , x 3 , x 4 , le cycle d, e, r a , r b , n et m ont les significations données dans la description, qui sont des inhibiteurs de la kinase ret et sont utiles dans le traitement et la prévention de maladies qui peuvent être traitées avec un inhibiteur de kinase ret, y compris des maladies et des troubles associés à ret.
MA46463A 2016-10-10 2017-10-10 Composés de pyrazolo[1,5-a]pyridine substitués en tant qu'inhibiteurs de la kinase ret MA46463B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662406275P 2016-10-10 2016-10-10
PCT/US2017/055993 WO2018071454A1 (fr) 2016-10-10 2017-10-10 Composés de pyrazolo[1,5-a]pyridine substitués en tant qu'inhibiteurs de la kinase ret

Publications (2)

Publication Number Publication Date
MA46463A MA46463A (fr) 2019-08-14
MA46463B1 true MA46463B1 (fr) 2022-10-31

Family

ID=65728635

Family Applications (1)

Application Number Title Priority Date Filing Date
MA46463A MA46463B1 (fr) 2016-10-10 2017-10-10 Composés de pyrazolo[1,5-a]pyridine substitués en tant qu'inhibiteurs de la kinase ret

Country Status (2)

Country Link
AR (1) AR109920A1 (fr)
MA (1) MA46463B1 (fr)

Also Published As

Publication number Publication date
MA46463A (fr) 2019-08-14
AR109920A1 (es) 2019-02-06

Similar Documents

Publication Publication Date Title
MA44674A (fr) Inhibiteurs de bromodomaine
JOP20190076A1 (ar) مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
JOP20190077A1 (ar) مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
MA40123A1 (fr) Pyrimidines utilisées en tant qu'inhibiteurs du facteur xia
MA42145A (fr) Triazoles agonistes du récepteur apj
MA43169B1 (fr) Composés héterocycliques en tant qu' inhibiteurs pi3k-gamma
MX393057B (es) Compuestos de indol carboxamida útiles como inhibidores de cinasas.
MA43828B1 (fr) Agents thérapeutiques pour maladies neurodégénératives
MA39898B1 (fr) Composés 4-amino-imidazoquinoline
JOP20190143A1 (ar) مثبطات جزيئات صغيرة من عائلة jak لإنزيمات الكيناز
MA41179A (fr) Composés inhibiteurs de parg
EA201691428A1 (ru) Бициклические гетероциклические производные в качестве ингибиторов irak4
MA46229B1 (fr) Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2
MY175865A (en) [1,2,4]triazolo[1,5-a]pyrimidine derivatives as protozoan proteasome inhibitors for the treatment of parasitic diseases such as leishmaniasis
EA200901474A1 (ru) Соли [4-(6-фтор-7-метиламино-2,4-диоксо-1,4-дигидро-2н-хиназолин-3-ил)фенил]-5-хлортиофен-2-илсульфонилмочевины в различных кристаллических формах и фармацевтические композиции на их основе
MA46965B1 (fr) Modulateurs de gamma ror (rory)
MA46462B1 (fr) Composés substitués de pyrazolo[1,5-a]pyridine en tant qu'inhibiteurs de la kinase ret
MA41311B1 (fr) Peptides antagonistes du cgrp
MA39533A1 (fr) Composés, composition pharmaceutique et leur utilisation dans le traitement de maladies neurodégénératives
EA202190578A1 (ru) ИНГИБИТОРЫ БЕЛОК-БЕЛКОВОГО ВЗАИМОДЕЙСТВИЯ KEAP1-Nrf2
EA201990939A1 (ru) ЗАМЕЩЕННЫЕ ПИРАЗОЛО[1,5-a]ПИРИДИНОВЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ RET КИНАЗЫ
EA201991473A1 (ru) Имидазопирролопиридин в качестве ингибиторов киназ семейства jak
MA44503B1 (fr) Composés de pyrrolotriazine en tant qu'inhibiteurs de tam
UA123899U (uk) Застосування солей тіазолію як агентів, що інгібують активність ацетилхолінестерази і бутирилхолінестерази
JOP20140372B1 (ar) مشتقات [4،2،1] ثلاثي أزولو[1،5-a] بيريميدين كمثبطات لبروتياسوم الأَوَالِي للاستخدام في علاج الأمراض الطفيلية كداء اللِّيشْمانِيَّاتِ